SARS-CoV-2 大流行对原发性免疫缺陷患者的影响。
Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.
机构信息
Research Center for Primary Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.
出版信息
J Clin Immunol. 2021 Feb;41(2):345-355. doi: 10.1007/s10875-020-00928-x. Epub 2020 Dec 1.
Abstract
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 1:1000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.
摘要
尽管据估计，50 岁以下感染人群中危及生命的 COVID-19 病例可能不到千分之一，但这种大流行对不同类型原发性免疫缺陷（PID）的儿科患者的实际影响尚不清楚。目前对 PID 患者国家注册中心的前瞻性研究表明，这些患者的感染发生率仅高出 1.23 倍，但死亡率却比主要为联合免疫缺陷和免疫失调患者的人群高出 10 倍。因此，应考虑进一步采用造血干细胞移植和免疫调节剂等方法来管理 COVID-19，以提高这两种 PID 实体的生存率。
相似文献
1
Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.SARS-CoV-2 大流行对原发性免疫缺陷患者的影响。
J Clin Immunol. 2021 Feb;41(2):345-355. doi: 10.1007/s10875-020-00928-x. Epub 2020 Dec 1.
2
Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel.新冠疫情对以色列原发性免疫缺陷患者的临床影响较小。
Front Immunol. 2021 Jan 14;11:614086. doi: 10.3389/fimmu.2020.614086. eCollection 2020.
3
COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico.COVID-19 与先天性免疫缺陷：来自墨西哥的 31 例患者的病例系列。
J Clin Immunol. 2021 Oct;41(7):1463-1478. doi: 10.1007/s10875-021-01077-5. Epub 2021 Jun 10.
4
Primary Immunodeficiency Diseases in COVID-19 Pandemic: A Predisposing or Protective Factor?新冠疫情中的原发性免疫缺陷疾病：是易感因素还是保护因素？
Am J Med Sci. 2020 Dec;360(6):740-741. doi: 10.1016/j.amjms.2020.07.027. Epub 2020 Jul 29.
5
Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review.宿主免疫和炎症反应在伴有基础原发性免疫缺陷的 COVID-19 病例中的作用：综述。
J Interferon Cytokine Res. 2020 Dec;40(12):549-554. doi: 10.1089/jir.2020.0210.
6
Primary immunodeficiency disease: a retrospective study of 112 Chinese children in a single tertiary care center.原发性免疫缺陷病：单中心 112 例儿童回顾性研究。
BMC Pediatr. 2019 Nov 4;19(1):410. doi: 10.1186/s12887-019-1729-7.
7
Vaccine-Derived Poliovirus Infection among Patients with Primary Immunodeficiency and Effect of Patient Screening on Disease Outcomes, Iran.原发性免疫缺陷患者中的疫苗衍生脊灰病毒感染及患者筛查对疾病结局的影响，伊朗。
Emerg Infect Dis. 2019 Nov;25(11):2005-2012. doi: 10.3201/eid2511.190540.
8
Risk Factors for Severe COVID-19 and Hospital Admission in Patients With Inborn Errors of Immunity - Results From a Multicenter Nationwide Study.先天性免疫缺陷患者发生重症 COVID-19 和住院的危险因素：一项多中心全国性研究结果
Front Immunol. 2022 Feb 28;13:835770. doi: 10.3389/fimmu.2022.835770. eCollection 2022.
9
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study.伴有或不伴有 Good 综合征的胸腺瘤患者的 COVID-19：一项单中心回顾性研究。
BMC Cancer. 2024 Jun 19;24(1):748. doi: 10.1186/s12885-024-12405-4.
10
Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative.美国国家 COVID 队列协作研究中儿童感染 SARS-CoV-2 的特征、结局和严重程度危险因素。
JAMA Netw Open. 2022 Feb 1;5(2):e2143151. doi: 10.1001/jamanetworkopen.2021.43151.
引用本文的文献
1
Evaluation of the effect of the COVID-19 pandemic on depression, anxiety and psychological resilience in patients with primary immunodeficiency.评估新冠疫情对原发性免疫缺陷患者抑郁、焦虑及心理复原力的影响。
BMC Immunol. 2025 May 19;26(1):39. doi: 10.1186/s12865-025-00721-8.
2
Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls.与健康对照相比，免疫缺陷患者接种5剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗后T细胞免疫增强，体液反应降低。
Front Immunol. 2025 Mar 6;16:1538453. doi: 10.3389/fimmu.2025.1538453. eCollection 2025.
3
Monitoring of immunoglobulin treatment compliance of patients with an inborn error of immunity during the pandemic period.大流行期间对先天性免疫缺陷患者免疫球蛋白治疗依从性的监测。
BMC Immunol. 2025 Mar 15;26(1):22. doi: 10.1186/s12865-025-00703-w.
4
SARS-CoV-2 excretion and genetic evolution in nasopharyngeal and stool samples from primary immunodeficiency and immunocompetent pediatric patients.原发性免疫缺陷和免疫功能正常儿科患者鼻咽及粪便样本中新冠病毒的排泄及基因进化
Virol J. 2025 Jan 13;22(1):9. doi: 10.1186/s12985-025-02628-7.
5
Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error.不同先天性免疫缺陷患者中新冠病毒病临床病程和结局的多样性可能与缺陷类型有关。
Adv Biomed Res. 2024 Nov 30;13:112. doi: 10.4103/abr.abr_134_23. eCollection 2024.
6
Clinical feature of omicron infection in children with inborn errors of immunity in China.中国先天性免疫缺陷患儿感染奥密克戎的临床特征。
Front Immunol. 2024 Jul 23;15:1420547. doi: 10.3389/fimmu.2024.1420547. eCollection 2024.
7
Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.儿科心理健康保健在 COVID-19 大流行期间：呼吁国际公共卫生行动。
Adv Exp Med Biol. 2024;1458:19-34. doi: 10.1007/978-3-031-61943-4_2.
8
Human genetic and immunological determinants of SARS-CoV-2 infection and multisystem inflammatory syndrome in children.儿童感染严重急性呼吸综合征冠状病毒2及多系统炎症综合征的人类遗传和免疫决定因素。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae062.
9
SARS-CoV-2 Seroepidemiology and Antibody Levels in Children during BA.5 Predominance Period.BA.5优势流行期儿童的新型冠状病毒2型血清流行病学及抗体水平
Diagnostics (Basel). 2024 May 17;14(10):1039. doi: 10.3390/diagnostics14101039.
10
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）在主要存在抗体缺陷的成年人中的疫苗反应。
J Allergy Clin Immunol Glob. 2024 Feb 20;3(2):100234. doi: 10.1016/j.jacig.2024.100234. eCollection 2024 May.
本文引用的文献
1
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.先天性免疫缺陷患者的 2019 年冠状病毒病：一项国际研究。
J Allergy Clin Immunol. 2021 Feb;147(2):520-531. doi: 10.1016/j.jaci.2020.09.010. Epub 2020 Sep 24.
2
Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases.气道中 ACE2 的表达：对慢性炎症性呼吸道疾病患者 COVID-19 风险和疾病管理的影响。
Clin Exp Allergy. 2020 Dec;50(12):1313-1324. doi: 10.1111/cea.13746. Epub 2020 Oct 6.
3
Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.评论：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入细胞依赖于血管紧张素转换酶2（ACE2）和跨膜丝氨酸蛋白酶2（TMPRSS2），并被一种临床验证有效的蛋白酶抑制剂阻断。
Front Oncol. 2020 Aug 19;10:1448. doi: 10.3389/fonc.2020.01448. eCollection 2020.
4
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
5
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
6
COVID-19 in a Child with Pre-Existing Immunodeficiency, Cardiomyopathy, and Chronic Pulmonary Disease.一名患有先天性免疫缺陷、心肌病和慢性肺病儿童的新型冠状病毒肺炎
Klin Padiatr. 2020 Sep;232(5):275-278. doi: 10.1055/a-1210-2639. Epub 2020 Aug 6.
7
The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.免疫系统作为 SARS-CoV-2 治疗靶点：COVID-19 免疫疗法的系统评价。
Life Sci. 2020 Oct 1;258:118185. doi: 10.1016/j.lfs.2020.118185. Epub 2020 Aug 1.
8
A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.一名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体多次检测不到的新型冠状病毒肺炎（COVID-19）患者。
J Appl Lab Med. 2020 Nov 1;5(6):1401-1405. doi: 10.1093/jalm/jfaa137.
9
The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections.环孢素的抗病毒特性。聚焦于冠状病毒、丙型肝炎病毒、流感病毒和人类免疫缺陷病毒感染。
Biology (Basel). 2020 Jul 28;9(8):192. doi: 10.3390/biology9080192.
10
Case Report: Systemic Inflammatory Response and Fast Recovery in a Pediatric Patient With COVID-19.病例报告：COVID-19 儿科患者的全身炎症反应和快速恢复。
Front Immunol. 2020 Jul 3;11:1665. doi: 10.3389/fimmu.2020.01665. eCollection 2020.
Zotero 插件